192 related articles for article (PubMed ID: 24525699)
1. Improved outcome with multimodal treatment and imatinib rechallenge in advanced GIST.
Gasparotto D; Miolo G; Torrisi E; Canzonieri V; Bertola G; Libra M; Marzotto A; Maestro R; Buonadonna A
Int J Colorectal Dis; 2014 May; 29(5):639-40. PubMed ID: 24525699
[No Abstract] [Full Text] [Related]
2. The role of surgical resection following imatinib treatment in patients with recurrent or metastatic gastrointestinal stromal tumors: results of propensity score analyses.
Park SJ; Ryu MH; Ryoo BY; Park YS; Sohn BS; Kim HJ; Kim CW; Kim KH; Yu CS; Yook JH; Kim BS; Kang YK
Ann Surg Oncol; 2014 Dec; 21(13):4211-7. PubMed ID: 24980089
[TBL] [Abstract][Full Text] [Related]
3. Is imatinib justified as an adjuvant chemotherapy for patients with recurrent gastrointestinal stromal tumors.
Lai IR; Hu RH; Chang KJ
Hepatogastroenterology; 2005; 52(63):826-8. PubMed ID: 15966213
[TBL] [Abstract][Full Text] [Related]
4. NCCN Task Force report: gastrointestinal stromal tumor (GIST).
Demetri G; DeMatteo RP
J Natl Compr Canc Netw; 2004 Sep; 2 Suppl 3():S-25-8. PubMed ID: 23570095
[No Abstract] [Full Text] [Related]
5. The effects of surgical cytoreduction prior to imatinib therapy on the prognosis of patients with advanced GIST.
An HJ; Ryu MH; Ryoo BY; Sohn BS; Kim KH; Oh ST; Yu CS; Yook JH; Kim BS; Kang YK
Ann Surg Oncol; 2013 Dec; 20(13):4212-8. PubMed ID: 24052319
[TBL] [Abstract][Full Text] [Related]
6. Gastrointestinal stromal tumor of the rectum: results of surgical and multimodality therapy in the era of imatinib.
Jakob J; Mussi C; Ronellenfitsch U; Wardelmann E; Negri T; Gronchi A; Hohenberger P
Ann Surg Oncol; 2013 Feb; 20(2):586-92. PubMed ID: 22965573
[TBL] [Abstract][Full Text] [Related]
7. Gastrointestinal stromal tumors: current management.
Pisters PW; Patel SR
J Surg Oncol; 2010 Oct; 102(5):530-8. PubMed ID: 20063363
[TBL] [Abstract][Full Text] [Related]
8. Long-term follow-up outcome of imatinib mesylate treatment for recurrent and unresectable gastrointestinal stromal tumors.
Saito S; Nakata K; Kajiura S; Ando T; Hosokawa A; Sugiyama T
Digestion; 2013; 87(1):47-52. PubMed ID: 23343969
[TBL] [Abstract][Full Text] [Related]
9. Imatinib adjuvant therapy after surgical excision of gastrointestinal stromal tumour.
Prescrire Int; 2011 Feb; 20(113):38. PubMed ID: 21488587
[No Abstract] [Full Text] [Related]
10. A multicenter long-term study of imatinib treatment for Japanese patients with unresectable or recurrent gastrointestinal stromal tumors.
Ogata K; Mochiki E; Ojima H; Haga N; Fukuchi M; Aihara R; Ando H; Uchida N; Toyomasu Y; Suzuki M; Kimura A; Kogure N; Yokobori T; Ohno T; Kuwano H
J Surg Oncol; 2014 Dec; 110(8):942-6. PubMed ID: 25164620
[TBL] [Abstract][Full Text] [Related]
11. [Surgical treatment of an advanced GIST the age of imatinib].
Fernández JA; Parrilla P
Cir Esp; 2009 Jul; 86(1):3-12. PubMed ID: 19539273
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant imatinib in locally advanced gastrointestinal stromal tumors (GIST): the EORTC STBSG experience.
Rutkowski P; Gronchi A; Hohenberger P; Bonvalot S; Schöffski P; Bauer S; Fumagalli E; Nyckowski P; Nguyen BP; Kerst JM; Fiore M; Bylina E; Hoiczyk M; Cats A; Casali PG; Le Cesne A; Treckmann J; Stoeckle E; de Wilt JH; Sleijfer S; Tielen R; van der Graaf W; Verhoef C; van Coevorden F
Ann Surg Oncol; 2013 Sep; 20(9):2937-43. PubMed ID: 23760587
[TBL] [Abstract][Full Text] [Related]
13. Surgical management in metastatic gastrointestinal stromal tumor (GIST) patients after imatinib mesylate treatment.
Yeh CN; Chen TW; Tseng JH; Liu YY; Wang SY; Tsai CY; Chiang KC; Hwang TL; Jan YY; Chen MF
J Surg Oncol; 2010 Nov; 102(6):599-603. PubMed ID: 20976730
[TBL] [Abstract][Full Text] [Related]
14. Role of surgery combined with kinase inhibition in the management of gastrointestinal stromal tumor (GIST).
Hohenberger P; Eisenberg B
Ann Surg Oncol; 2010 Oct; 17(10):2585-600. PubMed ID: 20407930
[TBL] [Abstract][Full Text] [Related]
15. Preoperative imatinib for patients with primary unresectable or metastatic/recurrent gastrointestinal stromal tumor.
Shen C; Chen H; Yin Y; Chen J; Zhang B; Chen Z; Chen J
Clinics (Sao Paulo); 2014 Nov; 69(11):758-62. PubMed ID: 25518034
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of 3-year vs 1-year adjuvant therapy with imatinib in patients with high risk of gastrointestinal stromal tumour recurrence in the Netherlands; a modelling study alongside the SSGXVIII/AIO trial.
Majer IM; Gelderblom H; van den Hout WB; Gray E; Verheggen BG
J Med Econ; 2013 Sep; 16(9):1106-19. PubMed ID: 23808902
[TBL] [Abstract][Full Text] [Related]
17. A study of the postoperative course in cases of GIST of the stomach. The efficacy of imatinib in cases of recurrence.
Higashi D; Watanabe Y; Hirano K; Shimomura T; Egawa Y; Tomiyasu T; Ishibashi Y; Futami K; Maekawa T; Ota A; Oshige K; Iwashita A
Anticancer Res; 2009 Nov; 29(11):4893-6. PubMed ID: 20032453
[TBL] [Abstract][Full Text] [Related]
18. Managing GIST in the imatinib era: optimization of adjuvant therapy.
Trent JC; Subramanian MP
Expert Rev Anticancer Ther; 2014 Dec; 14(12):1445-59. PubMed ID: 25340579
[TBL] [Abstract][Full Text] [Related]
19. Presentation and management of gastrointestinal stromal tumours.
Mongan AM; Malik V; Rowley S; Claxton Z; Muldoon C; O'Toole D; Ravi N; Reynolds JV
Ir Med J; 2013 Jun; 106(6):176-9. PubMed ID: 23909154
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of 3-years of adjuvant imatinib in gastrointestinal stromal tumors (GIST) in the United States.
Sanon M; Taylor DC; Parthan A; Coombs J; Paolantonio M; Sasane M
J Med Econ; 2013; 16(1):150-9. PubMed ID: 22762291
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
